Immune System and Transfer Factor - PowerPoint PPT Presentation

1 / 135
About This Presentation
Title:

Immune System and Transfer Factor

Description:

Parmely et al J. Dairy Science vol. 60(4) 1977 pp. 4LIFE TRANSFER FACTOR PATENT United States Patent [19] [11] Patent Number: 4,816,563 Wilson et al. [45] ... – PowerPoint PPT presentation

Number of Views:628
Avg rating:3.0/5.0
Slides: 136
Provided by: RobRob2
Category:

less

Transcript and Presenter's Notes

Title: Immune System and Transfer Factor


1
Immune System and Transfer Factor
2
Immune System
  • The health of the body is dependent on the immune
    system's ability to recognize and then react and
    remember germs and cancers.

3
Major Lines of Immune Defense
  • Innate Immunity
  • Passive Active
  • Skin
    Inflammatory Cells
  • Mucus
    Natural Killer Cells
  • Stomach Acid
    Phagocytic Cells
  • Tears
    Natural Antibodies
  • Interferon
    Complement proteins
  • Acquired Immunity
  • Active
  • B Cells
    Immune Memory cells
  • T Cells
    Antibodies

4
Characteristics of Innate and Acquired Immunity
  • Innate Acquired
  • Prior exposure to the Requires exposure to
  • microbe not required microbe
  • Nonspecific Specific
  • Repeat exposure does Memory for re-
  • not change response exposure
  • Natural antibodies Elicited antibodies
  • Complement system Cytotoxic Lymphocytes
  • Natural Killer cells Memory B and T
    cells
  • Phagocytes Plasma cells
    (antibodies)

5
The Innate Immune System
  • Cells (N K cells) are the 1st line defenders
    against cancer and infectious disease.
  • It initiates and improves the slower but more
    specific acquired immune response.

6
In 1949 H. Sherwood Lawrence, Ph.D. was
attempting to understand the immune response and
how it was conveyed.
7

-
-

-




8
Response to an Infectious Threat
Secondary Response
Primary Response
First Exposure
Second Exposure
Memory Cell
9
PRIMARY IMMUNE RESPONSE
10
PRIMARY IMMUNE RESPONSE
  • A cut in the skin damages cells and allows
    bacteria into the body signaling an immune
    response from macrophages and other scavenger
    immune cells.
  • Mast cells release chemicals that trigger
    inflammation, allowing other immune cells to rush
    to the problem area.
  • Before reinforcements arrive, macrophages and
    other prestationed immune cells start attacking
    bacteria, chop them up into bits called antigens.
  • They are then transported to lymph nodes where
    these macrophages attach to B cells and T cells.
    B cells begin producing antibodies specifically
    for the particular antigens or germs the body is
    exposed to.
  • The antibodies trigger responses from certain
    immune cells like NK cells, macrophages and
    killer T cells to engulf and kill the
    bacteria-infected cells.
  • Helper T cells signal the antibodies and killer T
    cells to go directly to the wound.
  • While the immune cells are taking care of the
    germs, other cells called platelets begin healing
    the wound by forming clots which close the wound

11
SECONDARY IMMUNE RESPONSE
12
SECONDARY IMMUNE RESPONSE
  • A cut in the skin damages cells and allows
    bacteria into the body signaling an immune
    response from macrophages and other scavenger
    immune cells.
  • Mast cells release chemicals that trigger
    inflammation, allowing other immune cells to rush
    to the problem area.
  • Before reinforcements arrive, macrophages and
    other pre-stationed immune cells start attacking
    bacteria, chop them up into bits called antigens.
  • B cells, set in motion by previous immune
    responses, begin producing antibodies
    specifically for the particular antigens or germs
    the body is exposed to. The antibodies trigger
    responses from certain immune cells like NK
    cells, macrophages and killer T cells to engulf
    and kill the bacteria-infected cells.
  • Helper T cells signal the antibodies and killer T
    cells to go directly to the wound.
  • While the immune cells are taking care of the
    germs, other cells called platelets begin healing
    the wound by forming clots which close the wound.

13
Secondary Immune Response
1. Early Recognition
2. Quick Response
3. Massive Response
Memory Molecule Is
4. Allows Us to Win The Numbers Game
Transfer Factor
5. Provides Resistance
6. Resistance Equals Immunity
7. Immunity Provides Protection
8. Key to Immunity - Memory Molecule
14
SOURCES OF TRANSFER FACTOR
  • BLOOD
  • (1949 LAWRENCE)
  • WHITE BLOODCELLS CALLED LYMPHOCYTES ARE REMOVED
    FROM BLOOD AND TRANSFER FACTORS ARE REMOVED FROM
    THEM.
  • EXPENSIVE BUT
  • EFFECTIVE. NOT
  • PRACTICAL FOR
  • GENERAL USE.
  • COLOSTRUM
  • (1989 WILSON/PADDOCK)
  • FIRST MATERNAL MILK PRODUCED RIGHT AT AND AFTER
    BIRTH. PATENTED SELECTIVE FILTRATION METHOD
    PERFECTED IN 1989 WHICH REMOVES TRANSFER FACTORS
    FROM COLOSTRUM.
  • ECONOMICAL AND
  • EFFECTIVE. PRACTICAL
  • FOR GENERAL USE.

15
Source of Transfer Factor
ULTRA FILTRATION
Dry
FILTER
  • NO PESTICIDES
  • NO ANTIBIOTICS
  • NO HORMONES

16
From the Cow to YouTransfer Factor Quality
  • Quality Assurance and Product Safety
    Communications
  • Dr. Rick Bennett

17
The TF Farms and Cows
  • Farms in the United States
  • Grade A Dairies
  • State and Federal quality controls
  • Pasture and Corral fed

18
Colostrum Production
  • Colostrum milked for the first day
  • Baby calves get plenty
  • Harvested as for Grade A Milk
  • Frozen on farm

19
Colostrum TF Processing
  • Frozen then thawedat plant
  • Defatted
  • Batch Pasteurized (LTLT)
  • Ultra-filtered to concentrate Transfer Factor
  • Low temp. sprayed dried

20
Quality Assurance HACCP
  • Known hazards
  • Documented interventions
  • Electronic monitoring

True QA !
21
Transfer Factor Safety Communications Key Points
  • USFDA Grade A Dairies
  • USDA and State Approved Food Processing Plants
  • Pasteurized Colostrum and TF Ultra-filtrate (3x
    Microbial safety control)
  • Antibiotics cannot be legally used in milking
    cows- Milk and colostrum routinely tested
  • rBST not generally used on TF farms
  • Mad Cow disease NOT present in US

22
Transfer Factor Quality Assured, Ready for
Product Formulation and You

23
IMPORTANT POINTS
  • DAIRY CATTLE PRODUCE LARGE AMOUNTS OF
    COLOSTRUM-MORE THAN THE CALF NEEDS.
  • TRANSFER FACTORS ARE THE SAME FOR ALL SPECIES.

HUMAN AND COW TRANSFER FACTORS ARE MOLECULARLY
IDENTICAL!!!
24
WHY NOT JUST COLOSTRUM?
  • COLOSTRUM
  • WATER
  • VITAMINS/MINERALS
  • PROTEIN
  • FAT
  • CARBORHYDRATES (LACTOSE)
  • IMMUNOGLOBULINS (SPECIES-SPECIFIC ANTIBODIES)
  • SLIGHT GROWTH HORMONE
  • TRANSFER FACTORS
  • TRANSFER FACTOR
  • TRANSFER FACTORS

IT IS ESTIMATED TO TAKE 45 GM OF COLOSTRUM (OR
45,000 MG) TO GET THE EQUIVALENT TRANSFER FACTORS
IN 600 MG OF 4LIFE TRANSFER FACTOR.
25
CHARACTERISTICS OF TRANSFER FACTORS
  • VERY SMALL POLYPEPTIDES (PROTEINS)
  • MOLECULAR WEIGHT lt 6000 DALTONS
  • THE SAME FOR ALL SPECIES
  • STABLE EVEN IN ACID ENVIRONMENT (NOT HYDROLYZED)
  • ABSORABLE IN ALL-AGED RECIPIENTS
  • NON-ALLERGENIC DUE TO SMALL SIZE
  • HALF-LIFE THOUGHT TO BE lt THREE WEEKS
  • ORAL ADMINISTRATION THOUGHT TO BE MOST EFFECTIVE
    ROUTE
  • NON-TOXIC
  • REMEMBER 3 TRANSFER FACTORS ARE THE SAME
    FOR ALL SPECIES!!

26
PROPERTIES OF TRANSFER FACTORS(3 FRACTIONS)
  • INDUCER TRIGGERS A GENERAL STATE
  • FRACTION OF READINESS IN THE IMMUNE
  • SYSTEM
  • ANTIGEN AN ARRAY OF CRITICAL TAGS
  • SPECIFIC USED BY THE IMMUNE SYSTEM
  • FRACTION TO IDENTIFY A HOST OF ENEMY
  • MICROBES
  • SUPPRESSOR DOWN-REGULATES THE IMMUNE
  • FRACTION RESPONSE ONCE THE THREAT
  • IS DEFEATED

27
Benefits of Transfer Factor
  • Emergence of new viruses or resurfacing of old
    pathogens.
  • Successful use in viral, parasitic, fungal,
    malignant, neurological and autoimmune diseases.
  • Cases of atopic dermatitis, herpes zoster
    ophthalmicus
  • l600 pts, good to excellent results in viral,
    cancer, fungal, CFS, AIDS and autoimmune diseases
    with no acute or chronic toxicity.
  • Congenital immunodeficiency, IgA, IgE
  • Antibiotic-resistant infections
  • Asthma
  • Psoriasis
  • Senility
  • Hepatitis B
  • The use of transfer factor in the prevention of
    illness and the maintenance of health is its
    greatest potential benefit and its safety when
    used chronically has been well demonstrated.
  • Excellent safety record with no adverse side
    effect even when administered in extreme excess
    or over several years in all age groups.

28
TF in the Intensive Care Unit15
  • 60 patients
  • immuno-deficiencies, diabetic patients
  • no time to wait for tests
  • 1 unit of TF 3/d for 3 days oral, IM or IV
  • improved response to conventional therapy
  • reduced hospitalization time

29
TF and Severe Pediatric Infections12
  • 45 patients
  • average age 4.2 yrs
  • unresponsive to conventional therapy
  • 43 cases reached remission
  • improvement even in the 2 other cases in spite of
    congenital IgA and IgG deficiency

30
TF and Severe Pediatric Infections12
  • 45 patients
  • average age 4.2 yrs
  • unresponsive to conventional therapy
  • 43 cases reached remission
  • improvement even in the 2 other cases in spite of
    congenital IgA and IgG deficiency

31
Atopic Dermatitis with Transfer Factor or
Cyclosporin A
  • 30 patients
  • Cellular immune deficiency
  • Unresponsive to conventional therapy
  • Both groups lowered eosinophils
  • Cyclosporin A lowered CD4 (helper)
  • TF raised CD8 (suppressor)

32
TRANSFER FACTOR
  • More than 3,000 publications
  • Clinical trials
  • International Congress on Transfer Factor (XI)

33
US PATENTS
  • 54 FOOD AND THE METHOD OF
  • EXTRACTING THE SAME FROM
  • COLOSTRUM AND MILK
  • 75 Inventors Mary E. Collins Robert A.
    Collins,
  • both of Waukon, Iowa
  • 73 Assignee Impro Porducts, Inc., Wankson,
    Iowa
  • 21 Appl. No. 276,230
  • 22 FiledJun. 22, 1981
  • Related U.S. Application Data
  • 63 Continuation-in-part of Ser. No. 154,502,
    May 29,
  • 1980, abandoned.
  • 51 Int. Cl.4....................................
    ........... 4A61K 39/00
  • 52 U.S. Cl. ....................................
    .... 424/85 426/583
  • 426/491
  • 53 Field of Search ...................426/580,
    583, 41, 431,
  • 426/491, 495, 657 424/85, 86, 87
  • 56 References Cited
  • U.S. PATENT DOCUMENTS
  • 3,128,230 4/1964 Helabach...................424/85

34
IMPORTANCE OF TRANSFER FACTOR(ORIGINS OF DISEASE)
  • THREATS
  • FROM OUTSIDE
  • 1. ALLERGIES
  • 2. INFECTIONS
  • THREATS
  • FROM WITHIN
  • 1. AUTO-IMMUNE
  • 2. CANCER

35
MAJORITY OF DISEASES
  • 1. ALLERGIES
  • 2. INFECTIONS
  • 3. AUTO-IMMUNE
  • 4. CANCER

ARE IMMUNE SYSTEM DYSFUNCTIONS
36
IF YOUR IMMUNE SYSTEM IS
  • UNDERACHIEVING
  • INFECTION
  • CANCER
  • NEED TO
  • STIMULATE
  • OVERACHIEVING
  • ALLERGIES
  • AUTO-IMMUNE
  • NEED TO
  • BALANCE

37
  • Transfer Factor is an
  • immunomodulator meaning it is best
  • utilized to balance the immune system
  • response. Remember Transfer
  • Factor has both INDUCER and
  • SUPPRESSOR fractions.

38
TRANSFER FACTOR
  • Immune Functionality's
  • ENHANCER
  • SUPPRESSOR
  • ANTIGEN SPECIFIC

39
TRANSFER FACTOR PLUS
  • 2ND GENERATION FORMULATION
  • DESIGNED BY
  • WILLIAM HENNEN, PH.D.
  • DIRECTOR OF RD 4LIFE RESEARCH
  • IMMUNO-STIMULANT

40
TRANSFER FACTOR PLUS
  • INGREDIENTS
  • TRANSFER FACTOR
  • CORDYCEPS
  • 3. GLUCANS
  • (YEAST, MAITAKE, SHIITAKE)
  • 4. MANNANS
  • (FROM ALOE VERA)
  • 5. IP-6
  • 6. THYMIC FACTORS

41
Lymphocytes
  • T cells helper T cell, cytotoxic T cells, DTH
    T cells
  • B cells pro-B cell, pre-B cell, immature B
    cell,
  • mature B cell
  • NK cells CD56bright, CD56dim
  • NKT cells NK like T cells
  • LAK cell lymphokine activated killer cells
  • ( T-LAK, NK-LAK)
  • TIL cell tumor-infiltrating lymphocytes

42
Pivotal role of NK cells in the immune system
  • NK cells
  • NKT cells

43
Innate immunity vs. adaptive immunity
  • Innate (non-specific)
  • - skin, monocytes/macrophage system, NK cells
    etc.
  • Adaptive (specific)
  • - humoral immunity (B cells)
  • - cellular immunity (T cells)

44
Interplay of Innate and Adaptive Immunity
  • The complement system is the merging point of
    innate and adaptive immunity. NK cells also
    produce a number of cytokines (messenger
    molecules) that are potent regulator of T cells.
  • Dendritic cells, like macrophages, capture
    foreign antigens, present them to other immune
    cells and trigger antibody production. They also
    produce cytokines in response to enveloped
    viruses (herpes simplex and HIV).

45
CD4-helper
CD8-suppressor
Th2
Th1
CTL Cytotoxicity
Suppressor
Innate
Humoral
Innate immunity i.e. macrophage Mediated with
little antibody
Adaptive immunity i.e. antibodies produced and
isotype class switching

Infected cell is killed




http//www.health.auckland.ac.nz/courses/Biosci357
/LecturesWeb/357Lecture11.htm
46
NKT cells (human)
  • Restricted TCR repertorie Va24-JaQ
  • Recognize MHC class I like CD1
  • Frequency
  • - PBL 0.1 0.5
  • - Liver 4 5
  • Cytokine production
  • - type 1 IFN-g, IL-2, TNF-b ? anti-cancer
    effect
  • - type 2 IL-4, IL-5, IL-10 ? prevent
    autoimmune disease

47
(No Transcript)
48
Natural Killer Cell (I)
  • 10 20 of lymphocytes in circulating blood
  • Natural resistance against tumors and virus
    infections etc.
  • Morphology Large Granular Lymphocytes
    (LGL)
  • Marker CD3-CD56CD16/-

49
Killer Cells
  • They target cells that are missing the self
    marker that identifies a cell as one of our own.
    Foreign cells without self markers are attacked.
  • Low NK cell activity cancer, congenital or
    acquired immunodeficiencies, severe viral
    infections, autoimmune diseases, behavioral
    disorders, several genetic disorders, chronic
    illness and infections.
  • The young, the old and the stressed are more
    susceptible to immunologic breakdown. This may
    allow tumors to grow faster.
  • Chronic fatigue immune dysfunction syndrome
  • (CFIDS) is associated with persistently low NK
    activity

50
(No Transcript)
51
(No Transcript)
52
Natural Killer Cell (II)
  • Cytolytic mechanism spontaneously killing Ab
    dependent Cellular Cytotoxicity (ADCC)
  • Cytolytic mediatros perforin/granzyme,
    Fas- ligand/Fas, TNF-a, NO
  • Self vs. non-self MHC class I ? negative signal

53
(No Transcript)
54
(No Transcript)
55
(No Transcript)
56
Natural Killer Cell (II)
  • Cytolytic mechanism spontaneously killing Ab
    dependent Cellular Cytotoxicity (ADCC)
  • Cytolytic mediatros perforin/granzyme,
    Fas- ligand/Fas, TNF-a, NO
  • Self vs. non-self MHC class I ? negative signal

57
(No Transcript)
58
(No Transcript)
59
(No Transcript)
60
(No Transcript)
61
(No Transcript)
62
Natural Killer Cell (III)
  • NK cell activation IFN-g, IL-2, IL-12, IL-18
    etc.
  • NK-cell precursor ? IL-15 ? Mature NK cell
  • NK cell subsets CD56bright , CD56dim

63
CD56 dim NK cells
  • Majority (90) of NK cells
  • gt95 of cells are CD16bright ? ADCC
  • are more toxic than CD56 bright cells.
  • produce low levels of cytokines.
  • are more granular than CD56 bight cells.
  • have relatively low proliferative capacity.
  • are less responsive to IL-2 induced
    proliferation.

64
(No Transcript)
65
  • KIR killer cell Ig-like receptor
  • MHC major histocompatibility complex
  • CD clusters of differention
  • CD94 C-type-lectin-inhibitory receptor
  • NKG2inhibitory variants
  • NCR natural cytotoxicity receptors
  • ILT Ig-like transcripts
  • APC antigen-presenting cells

66
CD56 bright NK cells
  • 10 of NK cells
  • have the capacity to produce abundant
    cytokines.
  • express high affinity IL-2 receptor (IL-2Rabg)
  • ? low doses of IL-2 ? proliferation,
    enhancement of cytotoxicity
  • major NK-cell subset in the uterus of a
    pregnant woman
  • are among the first lymphocytes to repopulate
    the


    peripheral blood
    following BMT.
  • clinical interest ? very low doses of IL-2 ?
    expand selectively this cell in cancer and HIV
    patients.

67
(No Transcript)
68
CYTOKINES
  • IFN Interferon
  • TNF tumor necrosis factor
  • IL interleukin
  • TGF transforming growth factors
  • CSF hematopoietic colony-stimulating factors

69
(No Transcript)
70
NK cells in disease
  • Cancer, Tuberculosis
  • - reduced NK cytotoxicity
  • AIDS
  • - low concentration of NK cells
  • - reduced NK cytotoxicity
  • Alzheimers disease
  • - increased NK cytotoxicity

71
NK cells and immunotherapy
  • Tumor therapy
  • Adv.
  • - activated NK cells are readily available for
    cancer therapy.
  • - expand rapidly in culture without prior
    sensitization.
  • Immunotherapy/chemotherapy
  • Immunotherapy/genetherapy

72
NK cells vs. ethanol
  • Diminished activation of NK cell lytic function
  • - decreased production of and response to
    IFN-alpha
  • - decreased levels of granzyme B and perforin

73
NK cells vs. aging
  • Impaired NK cytotoxicity
  • - decreased proliferative response to IL-2
  • the expansion of a mature NK cells
  • Stress NK cytotoxicity is suppressed.

74
NK cells vs. training
  • Increased the percentage of NK cells
  • - increased NK cell activity in the group on the
  • carbohydrate-rich diet
  • - decreased NK cell activity in the group on the
  • fat-rich diet

75
JANA STUDY WINTER 1999 DARRYL M. SEE, M.D.,
UNIVERSITY OF CALIFORNIA-IRVINE, IRVINE, CA
  • 196 PRODUCTS STUDIED WITH OVER 400 INGREDIENTS
  • STUDY WAS DESIGNED TO MEASURE NATURAL KILLER CELL
    ACTIVITY
  • NK CELLS ARE OUR FIRST LINE OF DEFENSE

76
(No Transcript)
77
JANA TEST RESULTS
  • PRODUCT
  • NONI
  • ALOE VERA
  • ENDOCRINE FORMULA
  • PHYTONUTRIENT FORMULA
  • BOVINE COLOSTRUM
  • CORDYCEPS
  • SHIITAKE
  • ECHINACEA (19 USE)
  • PLANT SUGARS FORMULA
  • IP-6
  • TRANSFER FACTOR
  • TRANSFER FACTOR PLUS
  • RISE OVER BASELINE
  • 1. 15
  • 2. 15
  • 3. 16
  • 4. 21
  • 5. 23
  • 6. 28
  • 7. 42
  • 8. 43
  • 9. 48
  • 10. 49
  • 11. 103
  • 12. 248

78
TRANSFER FACTOR PLUS ADVANCED FORMULA
  • 438 Increase in NK cell activity!!!

79
(No Transcript)
80
In a historic move, the Ministry of Health and
Social Development of the Russian Federation has
given approval to a dietary supplement for use in
comprehensive health care practice to 4Life. The
approval opens the way for the use of these
immune modulators in Russian hospitals.
81
Conducted by Dr. Darryl See On Stage 4 cancer
patients
Start prognosis Patients had 3.7 months to
live. Results after six months 16 out of the
20 patients studied
are in remission, either
improving or
in stable condition.
82
"There is no other product in a nutritional
substance, nor a drug, that has this kind of
power and ability to affect our immune system.
With the increase of killer viruses, mutated
germs, super-resistant germs, and food
contaminations, our only hope and defense, must
lie within our own immune system."
-- Darryl See, MD
Associate Clinical Professor WHO ( World Health
Organization) Western Europe, Dr. See received
his degree from the University of California,
Irvine. Academic appointments include
Assistant/Associate Clinical Professor of
Medicine Investigator, California Collaborative
Treatment Group and Infectious Disease
Consultant, Liver Transplantation Service. He has
received contracts, grants, and research awards
from Pfizer Pharmaceuticals, Upjohn
Pharmaceuticals, Roche Molecular Systems, Harvard
Biotechnology, National Institutes of Health,
Department of Defense, and more.
83
TRANSFER FACTOR
SEEKING BALANCE
SEEKING DOWN-REGULATION
  • ALLERGIES
  • AUTO-IMMUNE DISEASES

TRANSFER FACTOR PLUS
SEEKING STIMULATION
  • INFECTION
  • CANCER
  • PREVENTION

84
COMMONALITY HUMAN/BOVINE PATHOGENS
  • HUMAN PATHOGEN OR DISEASE BOVINE PATHOGEN
  • BACTERIA BACTERIA
  • TRAVELERS DIARRHEA (E. COLI) VERY TOXIGENIC E.
    COLI
  • VERY CAMPYLOBACTER JEJUNI
  • BLOODY DIARRHEA/HEMOLYTIC INCREASING E. COLI
    O157H7 VEROTOXIC
  • UREMIA
  • SALMONELLOSIS TYPHOID FEVER COMMON SALMONELLA
    THYPHIMURIUM,
  • SALMONELLA TYPHOSA DUBLIN
  • DIARRHEA, FROM FOOD AND WATER VERY CAMPYLOBACTER
    JEJUNI
  • CAUSING GUILLANE BARRE SYN.
  • LEPTOSPIROSIS (KIDNEY FAILURE) RARE LEPTOSPIRA
    (MANY SEROVARS)
  • UNDULANT FEVER RARE BRUCELLA ABORTUS
  • (BRUCELLA ABORTUS)
  • CLOSTRIDIAL INFECTION COMMON CLOSTRIDIA (MANY
    SPECIES)
  • (NON TETANUS) C. DIFFICILE
  • MYCOBACTERIUM INFECTIONS MYCOBACTERIUM SPECIES
  • AVIUM RARE

85
COMMONALITY CONTINUED
  • HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE
    PATHOGEN (CONT.)
  • BACTERIA (CONT.) BACTERIA (CONT.)
  • STAPHYLOCOCCAL SUPER INFECTIONS COMMON STAPH.
    AUREUS
  • STREPTOCOCCAL INFECTIONS COMMON STREPTOCOCCUS
  • ENDOCARDITIS COMMON BETA STREPTOCOCCUS
  • SUPERINFECTION INCREASING S. PYOGENES
  • S. PYOGENES INCREASING
  • ENTEROCOCCI COMMON ENTEROCOCCI (MOST SPECIES
    VRE) HOSPITAL AND VRE STRAINS
  • LISTERIOSIS AND ABORTION RARE LISTERIA
    MONOCYTOGENES
  • NEONATAL MENINGEOENCEPHALITIS RARE
  • HELIOBACTER PYLORI (ULCERS) COMMON BOVINE AND
    PORCINE
  • ASSOCIATION
  • VIRUSES VIRUSES
  • INFLUENZA COMMON INFLUENZA VIRUS
  • PNEUMONIA (RESP. SYNCYTIAL VIRUS) COMMON BOVINE
    RESP. SYNCYTIAL VIRUS

86
COMMONALITY CONTINUED
  • HUMAN PATHOGEN OR DISEASE (CONT.) BOVINE
    PATHOGEN (CONT.)
  • VIRUSES (CONT.) VIRUSES (CONT.)
  • CYTOMEGALOVIRUS COMMON BOVINE CMV AND IBR
  • HERPES INFECTIONS COMMON INFECTIOUS BOVINE
    RHINOTRACHEITIS
  • HIV (RETROVIRUS) COMMON BOVINE IMMUNE
    DEFICIENCY VIRUS
  • LENTIVIRUS (LOW PREVALENCE)
  • VENEZUELEAN EQUINE ENCEPHALITIS RARE BOVINE VEE
  • LYMPHOSARCOMA RARE BOVINE ONCOVIRUS
    LYMPHOSARC.
  • PSUEDOCOWPOX RARE BOVINE PARAPOXVIRUS
  • RHINOVIRUS (COMMON COLD) VERY COMMON BOVINE
    RHINOVIRUS
  • YEAST, FUNGI, PROTOZOA, OTHER MICROBES
  • ASPERGILLOSIS RARE ASPERGILLUS EXPOSURE COMMON
  • CANDIDIASIS COMMON CANDIDA EXPOSURE COMMON
  • CYCLOSPORA RARE ABORTIONS?
  • CRYPTOSPORIDIOSIS VERY COMMON CALF DIARRHEA, C.
    PARVUM

87
The Future of Medicine
Will focus on the Immune System
88
Lets talk about heart disease
89
A new test could save the lives of millions who
dont even know theyre in danger US News
World Report
90
  • TRADITIONAL RISK FACTORS that cant be changed
  • 1. Heredity
  • 2. Gender
  • 3. Increasing Age

91
  • TRADITIONAL RISK FACTORS that can be changed
  • 1. Smoking
  • 2. Cholesterol
  • 3. Hypertension
  • 4. Physical Inactivity
  • 5. Obesity
  • 6. Stress
  • 7. Substance Abuse

92
  • IMPORTANT NEWLY RECOGNIZED risk factors
  • 1. Homocysteine Levels
  • 2. C-Reactive Protein Levels

93
Homocysteine A Cardiovascular Risk Factor Worth
Considering
94
(No Transcript)
95
(No Transcript)
96
(No Transcript)
97
(No Transcript)
98
(No Transcript)
99
American Heart Disease Statistics
100
(No Transcript)
101
Strokes
  • 600,000 per year
  • 160,000 deaths per year
  • A stroke every 53 seconds
  • 1 death every 3.3 minutes
  • 4.5 million stroke survivors today

102
LAPD 4 year period death rate comparison
  • Heart Disease160
  • Gun shots5

103
Medical Sciences Solution to Heart Disease

Drugs
Surgery

Why does incidence remain the same?
104
Cross-section of normal coronary artery
105
Old theory of cholesterol plaque formation
106
Old theory of cholesterol plaque formation
107
Old theory of cholesterol plaque formation
108
(No Transcript)
109
(No Transcript)
110
  • Severe atherosclerosis with narrowing plaque
    formation, and hemorrhage

111
Effects of Elevated Homocysteine
  1. Damages inside lining of artery.
  2. Damage causes increased permeability (leakage).
  3. Germs and Bad Cholesterol (LDL) leak into
    arterial wall.
  4. Homocysteine oxidizes LDL Cholesterol.
  5. Oxidized LDL Cholesterol more dangerous form.

112
Effects of Elevated Homocysteine
  1. Germ-seeking Macrophages enter arterial wall.
  2. Macrophages get diverted. Start ingesting
    tasty oxidized LDL Cholesterol.
  3. Macrophages fill themselves with LDL Cholesterol.
    Look like they are filled with foam.
  4. These foam cells are what constitute plaques.
  5. Plaques cause ATHEROSCLEROSIS.

113
  • While commercial labs state that normal
    homocysteine levels can range from 5 to 15
    umol/L, a study published in Circulation Nov.
    15th, 1995 indicated that each 3 unit increase in
    homocysteine equals a 35 increase in cardiac
    risk.

114
(No Transcript)
115
All the patients were tested for antibodies a
sign of past infection to several bacteria and
viruses, including herpes simplex virus 1 and 2,
cytomegalovirus, Epstein-Barr virus, Haemophilus
influenzae, Chlamydia pneumoniae, Mycoplasma
pneumoniae and Helicobacter pylori.
116
C-Reactive Protein
  • C-Reactive Protein is a protein in the body whose
    level increases when there is inflammation. A
    study published in the New England Journal of
    Medicine involving 1086 apparently healthy men
    over an eight year period showed that those men
    with the highest level of C-Reactive Protein had
    a three-fold increase in the risk of heart attack
    and a two-fold increase in the risk of stroke.

117
(No Transcript)
118
(No Transcript)
119
(No Transcript)
120
(No Transcript)
121
(No Transcript)
122
(No Transcript)
123
Cardiovascular Evaluation
  • Homocysteine
  • Lipid profile (cholesterol)
  • C-Reactive Protein (CRP)

124
(No Transcript)
125
Homocysteine
  • Folic Acid
  • B6
  • B12

126
Cholesterol
  • Red rice yeast
  • Significantly reduces
  • Total Cholesterol
  • LDL (Bad) Cholesterol
  • Triglycerides
  • -Am J Clin Nutr 1999
  • Garlic

127
Inflammation (CRP)
  • Targeted Transfer Factor
  • Red Rice Yeast
  • Antioxidants


128
TF Cardio The Most Effective Cardiovascular
Supplement Ever!
  • Block Oxidative Damage
  • Selenium, Copper/Zinc, Resveratrol
  • Beta carotene, Vitamin C, Vitamin E
  • Balances Normal Blood Pressure Ranges
  • Copper, Magnesium
  • Improve Toxin Clearance
  • Folic Acid, Vitamins B6 B12, and Niacin
  • Increase the Pumping Efficiency of the Heart
  • Magnesium, CoQ10
  • Relax the Blood Vessels
  • Arginine, Mg, Ginkgo biloba, Hawthorne,
    Butchers Broom

129
French Paradox Lower incidence of Heart Disease
Resveratrol
  • Powerful Antioxidant
  • Reduces Blood Clotting
  • Increases HDL cholesterol (good cholesterol)
  • Bhat KPL, Kosmeder JW, 2nd. Antioxid Redox
    Signal 2001 2(6) 1041-64.

130
SUMMARY of the Problem
  • Heart Disease is the 1 Killer
  • Heart Disease is NOT a Simple Plumbing Problem
  • The Immune System is Critically Involved in Heart
    Disease
  • Infection may Initiate Heart Disease
  • Increased Homocysteine Levels add risk
  • Elevated C-Reactive Protein Levels add risk

131
SUMMARY of a Solution
  • Immune System Targeting to Fight Germs
    Suppress (Control) Inflammation
  • Help the Blood Vessels Relax
  • Protect the Heart and Arteries from Toxin and
    Oxidative Damage
  • Increase the Pumping Efficiency of the Heart
  • Decrease Homocysteine levels
  • Decrease Cholesterol levels
  • Decrease C-Reactive Protein levels

132
Health Supplement Timeline
Immune Support
2000s
Antioxidants
1990s
Herbs
1980s
Multivitamins
1970s
133
(No Transcript)
134
The credit belongs to the man who is actually in
the arena, whose face is marred by dust and sweat
and blood, who knows the great enthusiasms, the
great devotions, and spends himself in a worthy
cause who at best, if he wins, knows the thrills
of high achievement, and, if he fails, at least
fails daring greatly, so that his place shall
never be with those cold and timid souls who know
neither victory nor defeat.
Theodore Roosevelt
135
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com